Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
Type:
Grant
Filed:
June 9, 2021
Date of Patent:
January 30, 2024
Assignee:
CAYMAN CHEMICAL COMPANY, INC.
Inventors:
Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
Abstract: The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R1, R4, R5, R6, and L1 are as defined herein. Compounds of formula (IA) have been found useful as EP4 receptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders.
Type:
Grant
Filed:
March 12, 2019
Date of Patent:
May 31, 2022
Assignee:
Cayman Chemical Company, Inc.
Inventors:
Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo
Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
Type:
Grant
Filed:
January 2, 2020
Date of Patent:
July 20, 2021
Assignee:
CAYMAN CHEMICAL COMPANY, INC.
Inventors:
Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.
Type:
Grant
Filed:
July 18, 2014
Date of Patent:
August 4, 2020
Assignees:
CAYMAN CHEMICAL COMPANY, INC, MYOMETRICS LLC
Inventors:
Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Gregory William Endres, Fred Lawrence Ciske, Thomas Allen Owen, James Paul O'Malley
Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
Type:
Grant
Filed:
October 9, 2018
Date of Patent:
February 11, 2020
Assignee:
CAYMAN CHEMICAL COMPANY, INC.
Inventors:
Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Komilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
Abstract: The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R1, R4, R5, R6, and L1 are as defined herein. Compounds of formula (IA) have been found useful as EP4 receptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
March 13, 2018
Assignee:
CAYMAN CHEMICAL COMPANY, INC.
Inventors:
Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo
Abstract: Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.
Type:
Grant
Filed:
August 2, 2016
Date of Patent:
July 11, 2017
Assignees:
Cayman Chemical Company, Inc., Myometrics, LLC
Inventors:
Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Thomas Allen Owen, James Paul O'Malley
Abstract: Disclosed herein are compounds of formula (I) wherein L1, L2, L3, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
June 27, 2017
Assignee:
CAYMAN CHEMICAL COMPANY, INC.
Inventors:
Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Gregory William Endres, Andriy Komilov, James Bernard Kramer, Adam Uzieblo, Fred Lawrence Ciske, Kirk M. Maxey, James Paul O'Malley, Thomas Allen Owen
Abstract: Disclosed herein are compounds of formula (I) wherein L1, L2, L3, R1, R4, R5, and R6 are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
June 13, 2017
Assignee:
CAYMAN CHEMICAL COMPANY, INC.
Inventors:
Stephen Douglas Barrett, Bradlee David Germain, Adam Uzieblo, Fred Lawrence Ciske, Gregory William Endres, Andriy Kornilov, Kirk M. Maxey, James Paul O'Malley, Thomas Allen Owen
Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
Type:
Grant
Filed:
October 1, 2015
Date of Patent:
November 8, 2016
Assignee:
Cayman Chemical Company, Inc.
Inventors:
Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
Abstract: Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.
Type:
Grant
Filed:
July 19, 2013
Date of Patent:
September 13, 2016
Assignees:
Cayman Chemical Company, Inc., Myometrics, LLC
Inventors:
Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Thomas Allen Owen, James Paul O'Malley
Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.
Type:
Application
Filed:
July 18, 2014
Publication date:
June 9, 2016
Applicants:
CAYMAN CHEMICAL COMPANY, INC., MYOMETRICS LLC
Inventors:
Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Gregory William Endres, Fred Lawrence Ciske, Thomas Allen Owen, James Paul O'Malley
Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
Type:
Grant
Filed:
July 19, 2013
Date of Patent:
November 10, 2015
Assignee:
Cayman Chemical Company, Inc.
Inventors:
Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
Abstract: Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction of ocular hypertension.